Intra-articular hyaluronans: A review of product-specific safety profiles

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 5, 2003, Pages 296-309

  Hamburger, Max I ^a   Lakhanpal, Sharad ^b   Mooar, Pekka A ^c   Oster, David ^d  

^a Rheumatology Associates of Long Island   (United States)

^b Rheumatology Associates   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Denver Orthopedic Clinic   (United States)

Author keywords

Hyaluronans; Immunogenicity; Osteoarthritis of the knee; Safety

Indexed keywords

HYALURONIC ACID;

ANAPHYLAXIS; ARTICLE; DATA BASE; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE; KNEE OSTEOARTHRITIS; MEDLINE; PAIN; PRIORITY JOURNAL; PSEUDOGOUT;

EID: 0037393863     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.50008     Document Type: Article

References (51)

1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheumatism 2000;43:1905-15.
2. Hardingham TE. Cartilage: Aggrecan-link protein-hyaluronan aggregates. (Glycoforum 2000). Available at: http://www.glycoforum.gr.jp/science/hyaluronan/HA05/HA05E.html. Accessed June 20, 2002.
3. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Safety 2000;23: 115-30.
4. Balazs EA, Leschiner A, Leschiner A, Larsen N, Band P, inventors. Biomatrix Inc, assignee. Hylan preparation and method of recovery thereof from animal tissues. US Patent 5,099,013. November 16, 1990.
5. Allard S, O'Regan M. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 2000;22:792-5.
6. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998; 20:410-23.
7. Aviad AD, Houpt JB. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? J Rheumatol 1994;21:297-301.
8. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: Are the effects molecular weight dependent. Sem Arthritis Rheum 2002;32:10-37.
9. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993;1:97-103.
10. Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol 1993;20(suppl 39):16-8.
11. Adams ME, Atkinson MA, Lussier AJ, Schultz JI, Siminovitch KA, Wade JP, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti-inflammatory drugs (NSAIDs), and NSAIDs alone. Osteoarthritis Cartilage 1995;3: 213-26.
12. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritis knees with hylan: a treatment schedule study. Curr Ther Res 1994;55:220-32.
13. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potasher WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85.
14. Altman RD, Moskowitz R. Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998; 25:2203-12.
15. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology 1999;38: 602-7.
16. Hyalgan Premarket Approval Application: Summary of Safety and Effectiveness. Available at: http://www.fda.gov/ cdrh/pdf/p950027.pdf. Accessed August 22, 2000.
17. Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy, Ann Rheum Dis 1994;53:529-34.
18. Hyalgan (prescribing information). New York, NY: Sanofi Pharmaceuticals, Inc; 2000.
19. Kazimír J, Simkanin P, Báncziová E, Cafiková G, Polláková K, Treskonová E. Hyalgan in the treatment of osteoarthritis. A postmarketing study, January - June 1998 (Slovak, Summary in English and German). Rehabilitácia 1998;31: 221-37.
20. Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum 1998;41: 939-41.
21. Maillefert JF, Hirschhorn P, Pascaud F, Piroth C, Tavernier C. Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan. Rev Rhum 1997;10:593-4.
22. Maillefert JF, Tavernier C. Pyrophosphate arthritis after intraarticular injection of hyaluronan: comment on the article by Luzar and Altawil. Arthritis Rheum 1999;42:594.
23. Synvisc Premarket Approval Application: Summary of Safety and Effectiveness Data. Available at: http://www. fda.gov/cdrh/pdffp940015.pdf. Accessed August 22, 2000.
24. Synvisc (prescribing information). Philadelphia, PA: Wyeth-Ayerst; 2000.
25. Disla E, Infante R, Fahmy A, Karten I, Cuppari GG. Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Arthritis Rheum 1999;42:1302-3.
26. Ali Y, Weinstein M, Jokl P. Acute pseudogout following intra-articular injection of high molecular weight hyaluronic acid. Am J Med 1999;107:641-2.
27. Kroesen S, Schmid W, Theiler R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intraarticular injection of hylan G-F 20 (Synvisc). Clin Rheumatol 2000;19:147-9.
28. Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, Schumacher Jr. HR. Are there distinctive inflammatory flares of synovitis after Hylan GF intraarticular injections? Arthritis Rheum 1999;42(suppl 9):S29.
29. Puttick MP, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995;22:1311-4.
30. Allen E, Krohn K. Adverse reaction to hylan GF-20 (letter). J Rheumatol 2000;27:6.
31. Martens PB. Bilateral symmetric inflammatory reaction to hylan G-F 20 injection. Arthritis Rheum 2001;44:978-9.
32. Bernardeau C, Bucki B, Liote F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis 2001;60:518-20.
33. Rees JD, Wojtulewski JA. Systemic reaction to viscosupplementation for knee osteoarthritis. Rheumatology 2001; 40:1425-6.
34. Zardawi IM, Chan I. Synvisc perisynovitis. Pathology 2001;33:519-20.
35. Chen AL, Desai P, Adler EM, DiCesare PE. Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee. A report of six cases. J Bone Joint Surg 2002;84A: 1142-7.
36. Micheels P. Human anti-hyaluronic acid antibodies: is it possible? Dermatol Surg 2001;27:185-91.
37. US Food and Drug Administration MAUDE (Manufacture and User Facility Device Experience) Database. Available at: http://www.fda.gov/cdrh/databases.html. Accessed November 15, 2000 and April 30, 2002.
38. Harlow E, Lane D. Immunizations. In: Antibodies: A Laboratory Manual: 2000 Biosupplynet Source Book. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory 1988; 129-31.
39. Bucher W, Otto T, Hamburger MI. Possible mechanism for product-specific severe adverse reactions? Differentiation of hyaluronate products by qualitative differences in their immunogenicity in rabbits. Arthritis Rheum 2002;46:2543-4.
40. Goomer RS, Maris T, Amiel D. Immunogenicity of hyaluronic acid products: comparison of Synvisc and Artz in guinea pigs (abstract). Presented at: International Cartilage Research Society (ICRS) 4th Symposium (Session 22, #3); June 14-18, 2002; Toronto, CA.
41. Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long-term study. Eur J Rheum Inflamm 1995;15:57-62.
42. Kotz R, Kolarz G. Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop 1999;28(suppl 11):5-7.
43. Frizziero L, Reta M, Zizzi F, Piva S, Bologna LB, Terme A. Efficacy and safety of repeated treatment cycles of Hyalgan in knee osteoarthritis. Experience from the clinical practice. Presented at: American College of Rheumatology (ACR) 64th Annual Scientific Meeting; October-November 2, 2000; Philadelphia, PA.
44. Dahlberg L, Lohmander LS, Ryd L. Intra-articular injections of hyaluronan in patients with cartilage abnormalities and knee pain. Arthritis Rheum 1994;37:521-8.
45. Lohmander LS, Dalén N, Englund G, Hamalainen M, Jensen EM, Karlsson K, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Ann Rheum Dis 1996;55:424-31.
46. Puhl W, Bernau A, Greiling H, Köpcke W, Pförringer Q, Steck KJ, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage 1993;1:233-41.
47. Supartz (prescribing information). Tokyo, Japan: Seikagaku Corp; 2001.
48. Supartz Premarket Approval Application: Summary of Safety and Effectiveness Data. Available at: http://www. fda.gov/cdrh/pdf/p980044.html. Accessed August 23, 2001.
49. Carrabba M, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995;15:25-31.
50. Listrat V, Ayral X, Patarnello F, Bonvarlet J-P, Simonnet J, Amor B, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5: 153-60.
51. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999;21:1549-62.